Article
Ataluren Binds to Multiple Protein Synthesis Apparatus Sites and Competitively Inhibits Release Factor Dependent Termination
2022-03-23
Abstract excerpt
<title>Abstract</title> <p>Genetic diseases are often caused by nonsense mutations, but only one TRID (translation readthrough inducing drug), ataluren, has been approved for clinical use. Ataluren inhibits release factor complex (RFC) termination activity, while not affecting productive binding of near-cognate ternary complex (TC, aa-tRNA.eEF1A.GTP). Here we use photoaffinity labeling to identify two sites of at...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 614f4e08-d526-54d0-a11b-7bca4995f547
- DOI
- 10.21203/rs.3.rs-1451662/v1
